Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

Core Viewpoint - Xtant Medical Holdings, Inc. is focusing on a strategic shift towards higher-margin orthobiologics, supported by new product launches and a recent secondary private sale of shares, which enhances its operational flexibility and aligns with long-term healthcare-focused investors [1][2][3]. Group 1: Strategic Developments - The completion of a secondary private sale of 73.1 million shares by OrbiMed Advisors LLC to existing and new stockholders, led by Nantahala Capital Management LLC, marks a significant change in ownership structure [1]. - The termination of the investor rights agreement with OrbiMed allows Xtant greater strategic and operational flexibility moving forward [2]. - The company aims to prioritize profitability and self-sustainability as part of its long-term growth strategy, with a focus on expanding its orthobiologics offerings [3]. Group 2: Financial Performance - Xtant Medical expects to report Q1 2025 revenue between $32.8 million and$33.1 million, reflecting an 18% to 19% increase compared to Q1 2024 [4]. - The growth in revenue is primarily driven by orthobiologics and licensing revenue, indicating a successful transition towards higher-margin products [4]. Group 3: Future Outlook - The company plans several new product launches that will expand its offerings beyond spinal solutions, which is anticipated to accelerate growth in 2025 and beyond [3]. - Nantahala Capital Management expresses confidence in Xtant's innovative biologics and implant solutions, which address a growing need in the healthcare sector for regenerative and cost-effective surgical solutions [3].